Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1022-1027. doi: 10.1016/j.ijrobp.2017.03.034. Epub 2017 Mar 27.

Abstract

Purpose/objective(s): To estimate the association between different dose-volume metrics of the salivary glands and pharyngeal constrictors with patient reported severity of xerostomia/dysphagia in the setting of deintensified chemoradiation therapy (CRT).

Methods and materials: Forty-five patients were treated on a phase 2 study assessing the efficacy of deintensified CRT for favorable-risk, HPV-associated oropharyngeal squamous cell carcinoma. Patients received 60 Gy intensity modulated radiation therapy with concurrent weekly cisplatin (30 mg/m2), and reported the severity of their xerostomia/dysphagia (before and after treatment) using the patient-reported outcome version of the Common Terminology Criteria for Adverse Events (CTCAE) (PRO-CTCAE). Individual patient dosimetric data of the contralateral parotid and submandibular glands and pharyngeal constrictors were correlated with changes in PRO-CTCAE severity. A change in severity (from baseline) of ≥2 was considered clinically meaningful. Associations between dose-volume metrics and patient outcomes were assessed with receiver operating characteristic (ROC) curve and logistic regression model.

Results: Six months after CRT, patients reporting <2 change in xerostomia severity (n=14) had an average Dmean = 22 ± 9 Gy to the sum of the contralateral glands (parotid + submandibular) compared with the patients reporting ≥2 change (n=21), who had an average Dmean = 34 ± 8 Gy. V15 to V55 for the combined contralateral glands showed the strongest association with xerostomia (area under the curve [AUC] = 0.83-0.86). Based on the regression analysis, a 20% risk of toxicity was associated with V15 = 48%, V25 = 30%, and Dmean=21 Gy. Six months after CRT, patients reporting <2 change in dysphagia severity (n=26) had an average V55 = 76 ± 13 (%) to the superior pharyngeal constrictor compared with the patients reporting ≥2 change in severity (n=9), who had average V55 = 89 ± 13 (%). V55to V60 had the strongest association with dysphagia (AUC = 0.70-0.75). Based on the regression analysis, a 20% risk of toxicity was associated with V55 = 78%, V60 = 40%. The findings at 12 months were similar.

Conclusions: After deintensified CRT, the rate of patient-reported xerostomia/dysphagia appears to be associated with the V15 of the combined contralateral salivary glands and V55 to V60 of the superior pharyngeal constrictors.

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Area Under Curve
  • Carcinoma, Squamous Cell / therapy*
  • Carcinoma, Squamous Cell / virology*
  • Chemoradiotherapy / adverse effects*
  • Chemoradiotherapy / methods
  • Cisplatin / administration & dosage
  • Deglutition Disorders / etiology*
  • Esophagus / radiation effects
  • Humans
  • Oropharyngeal Neoplasms / therapy*
  • Oropharyngeal Neoplasms / virology*
  • Papillomaviridae*
  • Parotid Gland / radiation effects
  • Pharyngeal Muscles / radiation effects
  • Radiotherapy Dosage
  • Radiotherapy, Intensity-Modulated / methods
  • Severity of Illness Index
  • Submandibular Gland / radiation effects
  • Xerostomia / etiology*

Substances

  • Antineoplastic Agents
  • Cisplatin